Catabasis
Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage drug
development company built on a pathway pharmacology technology platform,
today announced that Catabasis will present an overview of its chemistry
platform at the American Chemical Society National Conference. The
American Chemical Society National Conference will be held August 16 -
20, 2015, in Boston, MA.
-
Michael Jirousek, Ph.D., chief scientific officer, will present
“Catabasis: A biotech start-up based on an innovative chemistry
platform,” during the Starting-Up & Spinning-Out: Commercializing
Innovative Chemistry session on August 18, 2015, at 10:25am local time
at the Westin Boston Waterfront Hotel.
About CAT-1004
CAT-1004 is an oral small molecule that
inhibits activated NF-kB, a protein that coordinates cellular response
to muscular damage, stress and inflammation and plays an important role
in muscle health. In skeletal muscle, activated NF-kB drives muscle
degeneration and suppresses muscle regeneration. In animal models of
DMD, CAT-1004 inhibited activated NF-kB, reduced muscle inflammation and
degeneration and increased muscle regeneration. In Phase 1 clinical
trials, CAT-1004 inhibited activated NF-kB and was well-tolerated with
no observed safety concerns. The FDA has granted CAT-1004 orphan drug
and fast track designations for the treatment of DMD.
About CAT-2054
CAT-2054 is an investigational oral drug
initially being developed for the treatment of hypercholesterolemia in
patients for whom existing therapies are insufficient. By modulating the
SREBP pathway, CAT-2054 may inhibit production of important cholesterol
metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase
and NPC1L1. If approved, CAT-2054, may have the potential to be the
first therapy to simultaneously modulate cholesterol synthesis,
clearance and absorption.
About Catabasis
Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of novel
therapeutics using its proprietary Safely Metabolized And Rationally
Targeted, or SMART, linker technology platform. The Company's SMART
linker technology platform is based on the concept of treating diseases
by simultaneously modulating multiple targets in one or more related
disease pathways. The Company engineers bi-functional product candidates
that are conjugates of two molecules, or bioactives, each with known
pharmacological activity, joined by one of its proprietary SMART
linkers. The SMART linker conjugates are designed for enhanced efficacy
and improved safety and tolerability. The Company’s focus is on
treatments for rare diseases. The Company is also developing other
product candidates for the treatment of serious lipid disorders. For
more information on the Company's technology and pipeline of drug
candidates, please visit www.catabasis.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150811005124/en/
Copyright Business Wire 2015